$235 million CAFC decision creates confusion around skinny-label generics, says dissenting judge
The Federal Circuit hands down its second ruling in the carvedilol dispute between Teva and GSK, following widespread concern over its first
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.